Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Characterization of Student Drinking Behaviors at the Beginning of the First Academic Year at One University in Southern Italy.

De Salvia MA, DʼUggento AM, Aquilino G, Tattoli M, Finelli C, Imbrici P, Desaphy JF, Giustino A.

J Addict Nurs. 2019 Jul/Sep;30(3):193-200. doi: 10.1097/JAN.0000000000000288.

PMID:
31478967
2.

Binding mode information improves fragment docking.

Jacquemard C, Drwal MN, Desaphy J, Kellenberger E.

J Cheminform. 2019 Mar 22;11(1):24. doi: 10.1186/s13321-019-0346-7.

3.

Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options.

Camerino GM, Fonzino A, Conte E, De Bellis M, Mele A, Liantonio A, Tricarico D, Tarantino N, Dobrowolny G, Musarò A, Desaphy JF, De Luca A, Pierno S.

Sci Rep. 2019 Feb 28;9(1):3185. doi: 10.1038/s41598-019-39676-3.

4.

Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate.

Farinato A, Altamura C, Imbrici P, Maggi L, Bernasconi P, Mantegazza R, Pasquali L, Siciliano G, Lo Monaco M, Vial C, Sternberg D, Carratù MR, Conte D, Desaphy JF.

Pharmacol Res. 2019 Mar;141:224-235. doi: 10.1016/j.phrs.2019.01.004. Epub 2019 Jan 3.

PMID:
30611854
5.

The analysis of myotonia congenita mutations discloses functional clusters of amino acids within the CBS2 domain and the C-terminal peptide of the ClC-1 channel.

Altamura C, Lucchiari S, Sahbani D, Ulzi G, Comi GP, D'Ambrosio P, Petillo R, Politano L, Vercelli L, Mongini T, Dotti MT, Cardani R, Meola G, Lo Monaco M, Matthews E, Hanna MG, Carratù MR, Conte D, Imbrici P, Desaphy JF.

Hum Mutat. 2018 Sep;39(9):1273-1283. doi: 10.1002/humu.23581. Epub 2018 Jul 4.

PMID:
29935101
6.

Structural Insights on Fragment Binding Mode Conservation.

Drwal MN, Bret G, Perez C, Jacquemard C, Desaphy J, Kellenberger E.

J Med Chem. 2018 Jul 26;61(14):5963-5973. doi: 10.1021/acs.jmedchem.8b00256. Epub 2018 Jul 3.

PMID:
29906118
7.

Mapping ligand binding pockets in chloride ClC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid.

Altamura C, Mangiatordi GF, Nicolotti O, Sahbani D, Farinato A, Leonetti F, Carratù MR, Conte D, Desaphy JF, Imbrici P.

Br J Pharmacol. 2018 May;175(10):1770-1780. doi: 10.1111/bph.14192. Epub 2018 Apr 6.

8.

IChem: A Versatile Toolkit for Detecting, Comparing, and Predicting Protein-Ligand Interactions.

Da Silva F, Desaphy J, Rognan D.

ChemMedChem. 2018 Mar 20;13(6):507-510. doi: 10.1002/cmdc.201700505. Epub 2017 Nov 7.

9.

Coexistence of CLCN1 and SCN4A mutations in one family suffering from myotonia.

Maggi L, Ravaglia S, Farinato A, Brugnoni R, Altamura C, Imbrici P, Camerino DC, Padovani A, Mantegazza R, Bernasconi P, Desaphy JF, Filosto M.

Neurogenetics. 2017 Dec;18(4):219-225. doi: 10.1007/s10048-017-0525-5. Epub 2017 Oct 9.

PMID:
28993909
10.

Effects of Benzothiazolamines on Voltage-Gated Sodium Channels.

Farinato A, Altamura C, Desaphy JF.

Handb Exp Pharmacol. 2018;246:233-250. doi: 10.1007/164_2017_46. Review.

PMID:
28939972
11.

Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study.

Camerino GM, Musumeci O, Conte E, Musaraj K, Fonzino A, Barca E, Marino M, Rodolico C, Tricarico D, Camerino C, Carratù MR, Desaphy JF, De Luca A, Toscano A, Pierno S.

Front Pharmacol. 2017 Jul 27;8:500. doi: 10.3389/fphar.2017.00500. eCollection 2017.

12.

A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions.

Imbrici P, Altamura C, Gualandi F, Mangiatordi GF, Neri M, De Maria G, Ferlini A, Padovani A, D'Adamo MC, Nicolotti O, Pessia M, Conte D, Filosto M, Desaphy JF.

Mol Cell Neurosci. 2017 Sep;83:6-12. doi: 10.1016/j.mcn.2017.06.006. Epub 2017 Jun 28.

PMID:
28666963
13.

Are induced fit protein conformational changes caused by ligand-binding predictable? A molecular dynamics investigation.

Gao C, Desaphy J, Vieth M.

J Comput Chem. 2017 Jun 5;38(15):1229-1237. doi: 10.1002/jcc.24714. Epub 2017 Apr 16.

PMID:
28419481
14.

Do Fragments and Crystallization Additives Bind Similarly to Drug-like Ligands?

Drwal MN, Jacquemard C, Perez C, Desaphy J, Kellenberger E.

J Chem Inf Model. 2017 May 22;57(5):1197-1209. doi: 10.1021/acs.jcim.6b00769. Epub 2017 Apr 26.

PMID:
28414463
15.

Toward precision medicine in myotonic syndromes.

De Bellis M, Camerino DC, Desaphy JF.

Oncotarget. 2017 Feb 28;8(9):14279-14280. doi: 10.18632/oncotarget.15263. No abstract available.

16.

Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.

De Bellis M, Carbonara R, Roussel J, Farinato A, Massari A, Pierno S, Muraglia M, Corbo F, Franchini C, Carratù MR, De Luca A, Conte Camerino D, Desaphy JF.

Neuropharmacology. 2017 Feb;113(Pt A):206-216. doi: 10.1016/j.neuropharm.2016.10.013. Epub 2016 Oct 13.

17.

Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin.

Camerino GM, De Bellis M, Conte E, Liantonio A, Musaraj K, Cannone M, Fonzino A, Giustino A, De Luca A, Romano R, Camerino C, Laghezza A, Loiodice F, Desaphy JF, Conte Camerino D, Pierno S.

Toxicol Appl Pharmacol. 2016 Sep 1;306:36-46. doi: 10.1016/j.taap.2016.06.032. Epub 2016 Jul 1.

PMID:
27377005
18.

Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: a paradigm to understand and treat ion channelopathies.

Imbrici P, Altamura C, Camerino GM, Mangiatordi GF, Conte E, Maggi L, Brugnoni R, Musaraj K, Caloiero R, Alberga D, Marsano RM, Ricci G, Siciliano G, Nicolotti O, Mora M, Bernasconi P, Desaphy JF, Mantegazza R, Camerino DC.

FASEB J. 2016 Oct;30(10):3285-3295. Epub 2016 Jun 20.

19.

Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.

Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D.

Front Pharmacol. 2016 May 10;7:121. doi: 10.3389/fphar.2016.00121. eCollection 2016. Review.

20.

Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation.

Desaphy JF, Carbonara R, D'Amico A, Modoni A, Roussel J, Imbrici P, Pagliarani S, Lucchiari S, Lo Monaco M, Conte Camerino D.

Neurology. 2016 May 31;86(22):2100-8. doi: 10.1212/WNL.0000000000002721. Epub 2016 Apr 29.

21.

Editorial: Recent Advances in Voltage-Gated Sodium Channels, their Pharmacology and Related Diseases.

Chahine M, Desaphy JF.

Front Pharmacol. 2016 Feb 8;7:20. doi: 10.3389/fphar.2016.00020. eCollection 2016. No abstract available.

22.

In vivo longitudinal study of rodent skeletal muscle atrophy using ultrasonography.

Mele A, Fonzino A, Rana F, Camerino GM, De Bellis M, Conte E, Giustino A, Conte Camerino D, Desaphy JF.

Sci Rep. 2016 Feb 1;6:20061. doi: 10.1038/srep20061.

23.

IChemPIC: A Random Forest Classifier of Biological and Crystallographic Protein-Protein Interfaces.

Da Silva F, Desaphy J, Bret G, Rognan D.

J Chem Inf Model. 2015 Sep 28;55(9):2005-14. doi: 10.1021/acs.jcim.5b00190. Epub 2015 Sep 14.

PMID:
26344157
24.

Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres.

Carbonara R, Carocci A, Roussel J, Crescenzo G, Buonavoglia C, Franchini C, Lentini G, Camerino DC, Desaphy JF.

Front Pharmacol. 2015 Jul 24;6:155. doi: 10.3389/fphar.2015.00155. eCollection 2015.

25.

ClC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation.

Imbrici P, Maggi L, Mangiatordi GF, Dinardo MM, Altamura C, Brugnoni R, Alberga D, Pinter GL, Ricci G, Siciliano G, Micheli R, Annicchiarico G, Lattanzi G, Nicolotti O, Morandi L, Bernasconi P, Desaphy JF, Mantegazza R, Camerino DC.

J Physiol. 2015 Sep 15;593(18):4181-99. doi: 10.1113/JP270358. Epub 2015 Jul 14.

26.

Effects of Nandrolone in the Counteraction of Skeletal Muscle Atrophy in a Mouse Model of Muscle Disuse: Molecular Biology and Functional Evaluation.

Camerino GM, Desaphy JF, De Bellis M, Capogrosso RF, Cozzoli A, Dinardo MM, Caloiero R, Musaraj K, Fonzino A, Conte E, Jagerschmidt C, Namour F, Liantonio A, De Luca A, Conte Camerino D, Pierno S.

PLoS One. 2015 Jun 11;10(6):e0129686. doi: 10.1371/journal.pone.0129686. eCollection 2015.

27.

Clinical, Molecular, and Functional Characterization of CLCN1 Mutations in Three Families with Recessive Myotonia Congenita.

Portaro S, Altamura C, Licata N, Camerino GM, Imbrici P, Musumeci O, Rodolico C, Conte Camerino D, Toscano A, Desaphy JF.

Neuromolecular Med. 2015 Sep;17(3):285-96. doi: 10.1007/s12017-015-8356-8. Epub 2015 May 26.

28.

ClC-1 chloride channels: state-of-the-art research and future challenges.

Imbrici P, Altamura C, Pessia M, Mantegazza R, Desaphy JF, Camerino DC.

Front Cell Neurosci. 2015 Apr 27;9:156. doi: 10.3389/fncel.2015.00156. eCollection 2015. Review.

29.

sc-PDB: a 3D-database of ligandable binding sites--10 years on.

Desaphy J, Bret G, Rognan D, Kellenberger E.

Nucleic Acids Res. 2015 Jan;43(Database issue):D399-404. doi: 10.1093/nar/gku928. Epub 2014 Oct 9.

30.

Beware of machine learning-based scoring functions-on the danger of developing black boxes.

Gabel J, Desaphy J, Rognan D.

J Chem Inf Model. 2014 Oct 27;54(10):2807-15. doi: 10.1021/ci500406k. Epub 2014 Sep 24.

PMID:
25207678
31.

Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita.

Lo Monaco M, D'Amico A, Luigetti M, Desaphy JF, Modoni A.

Clin Neurophysiol. 2015 Feb;126(2):399-403. doi: 10.1016/j.clinph.2014.06.008. Epub 2014 Jun 25.

PMID:
25065301
32.

sc-PDB-Frag: a database of protein-ligand interaction patterns for Bioisosteric replacements.

Desaphy J, Rognan D.

J Chem Inf Model. 2014 Jul 28;54(7):1908-18. doi: 10.1021/ci500282c. Epub 2014 Jul 17.

PMID:
24991975
33.

Actin sliding velocity on pure myosin isoforms from hindlimb unloaded mice.

Maffei M, Longa E, Qaisar R, Agoni V, Desaphy JF, Camerino DC, Bottinelli R, Canepari M.

Acta Physiol (Oxf). 2014 Dec;212(4):316-29. doi: 10.1111/apha.12320. Epub 2014 Jun 30.

PMID:
24888432
34.

Protein kinase C theta (PKCθ) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: a biophysical and gene expression study in mouse models lacking the PKCθ.

Camerino GM, Bouchè M, De Bellis M, Cannone M, Liantonio A, Musaraj K, Romano R, Smeriglio P, Madaro L, Giustino A, De Luca A, Desaphy JF, Camerino DC, Pierno S.

Pflugers Arch. 2014 Dec;466(12):2215-28. doi: 10.1007/s00424-014-1495-1. Epub 2014 Mar 20.

PMID:
24643479
35.

Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.

Desaphy JF, Carbonara R, Costanza T, Conte Camerino D.

Exp Neurol. 2014 May;255:96-102. doi: 10.1016/j.expneurol.2014.02.023. Epub 2014 Mar 5.

36.

N-aryl-2,6-dimethylbenzamides, a new generation of tocainide analogues as blockers of skeletal muscle voltage-gated sodium channels.

Muraglia M, De Bellis M, Catalano A, Carocci A, Franchini C, Carrieri A, Fortugno C, Bertucci C, Desaphy JF, De Luca A, Conte Camerino D, Corbo F.

J Med Chem. 2014 Mar 27;57(6):2589-600. doi: 10.1021/jm401864b. Epub 2014 Mar 7.

PMID:
24568674
37.

Effects of pleiotrophin overexpression on mouse skeletal muscles in normal loading and in actual and simulated microgravity.

Camerino GM, Pierno S, Liantonio A, De Bellis M, Cannone M, Sblendorio V, Conte E, Mele A, Tricarico D, Tavella S, Ruggiu A, Cancedda R, Ohira Y, Danieli-Betto D, Ciciliot S, Germinario E, Sandonà D, Betto R, Camerino DC, Desaphy JF.

PLoS One. 2013 Aug 28;8(8):e72028. doi: 10.1371/journal.pone.0072028. eCollection 2013.

38.

Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes.

Desaphy JF, Gramegna G, Altamura C, Dinardo MM, Imbrici P, George AL Jr, Modoni A, Lomonaco M, Conte Camerino D.

Exp Neurol. 2013 Oct;248:530-40. doi: 10.1016/j.expneurol.2013.07.018. Epub 2013 Aug 8.

39.

Paracrine effects of IGF-1 overexpression on the functional decline due to skeletal muscle disuse: molecular and functional evaluation in hindlimb unloaded MLC/mIgf-1 transgenic mice.

Pierno S, Camerino GM, Cannone M, Liantonio A, De Bellis M, Digennaro C, Gramegna G, De Luca A, Germinario E, Danieli-Betto D, Betto R, Dobrowolny G, Rizzuto E, Musarò A, Desaphy JF, Camerino DC.

PLoS One. 2013 Jun 3;8(6):e65167. doi: 10.1371/journal.pone.0065167. Print 2014.

40.

A large cohort of myotonia congenita probands: novel mutations and a high-frequency mutation region in exons 4 and 5 of the CLCN1 gene.

Brugnoni R, Kapetis D, Imbrici P, Pessia M, Canioni E, Colleoni L, de Rosbo NK, Morandi L, Cudia P, Gashemi N, Bernasconi P, Desaphy JF, Conte D, Mantegazza R.

J Hum Genet. 2013 Sep;58(9):581-7. doi: 10.1038/jhg.2013.58. Epub 2013 Jun 6.

PMID:
23739125
41.

An olive oil-derived antioxidant mixture ameliorates the age-related decline of skeletal muscle function.

Pierno S, Tricarico D, Liantonio A, Mele A, Digennaro C, Rolland JF, Bianco G, Villanova L, Merendino A, Camerino GM, De Luca A, Desaphy JF, Camerino DC.

Age (Dordr). 2014 Feb;36(1):73-88. doi: 10.1007/s11357-013-9544-9. Epub 2013 May 30.

42.

Recent advances in voltage-gated sodium channels, their pharmacology, and related diseases.

Desaphy JF, Chahine M.

Front Pharmacol. 2013 Apr 18;4:52. doi: 10.3389/fphar.2013.00052. eCollection 2013. No abstract available.

43.

Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.

De Bellis M, De Luca A, Desaphy JF, Carbonara R, Heiny JA, Kennedy A, Carocci A, Cavalluzzi MM, Lentini G, Franchini C, Camerino DC.

Biophys J. 2013 Jan 22;104(2):344-54. doi: 10.1016/j.bpj.2012.11.3830.

44.

Encoding protein-ligand interaction patterns in fingerprints and graphs.

Desaphy J, Raimbaud E, Ducrot P, Rognan D.

J Chem Inf Model. 2013 Mar 25;53(3):623-37. doi: 10.1021/ci300566n. Epub 2013 Mar 6.

PMID:
23432543
45.

Molecular dissection of lubeluzole use-dependent block of voltage-gated sodium channels discloses new therapeutic potentials.

Desaphy JF, Carbonara R, Costanza T, Lentini G, Cavalluzzi MM, Bruno C, Franchini C, Camerino DC.

Mol Pharmacol. 2013 Feb;83(2):406-15. doi: 10.1124/mol.112.080804. Epub 2012 Nov 21.

PMID:
23175529
46.

Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy.

Desaphy JF, Modoni A, Lomonaco M, Camerino DC.

Eur J Clin Pharmacol. 2013 Apr;69(4):1037-9. doi: 10.1007/s00228-012-1414-3. Epub 2012 Oct 3. No abstract available.

47.

In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia.

Desaphy JF, Costanza T, Carbonara R, Conte Camerino D.

Neuropharmacology. 2013 Feb;65:21-7. doi: 10.1016/j.neuropharm.2012.09.006. Epub 2012 Sep 18.

48.

Structural insights into the molecular basis of the ligand promiscuity.

Sturm N, Desaphy J, Quinn RJ, Rognan D, Kellenberger E.

J Chem Inf Model. 2012 Sep 24;52(9):2410-21. Epub 2012 Sep 5.

PMID:
22920885
49.

Comparison and druggability prediction of protein-ligand binding sites from pharmacophore-annotated cavity shapes.

Desaphy J, Azdimousa K, Kellenberger E, Rognan D.

J Chem Inf Model. 2012 Aug 27;52(8):2287-99. doi: 10.1021/ci300184x. Epub 2012 Aug 16.

PMID:
22834646
50.

Adaptation of mouse skeletal muscle to long-term microgravity in the MDS mission.

Sandonà D, Desaphy JF, Camerino GM, Bianchini E, Ciciliot S, Danieli-Betto D, Dobrowolny G, Furlan S, Germinario E, Goto K, Gutsmann M, Kawano F, Nakai N, Ohira T, Ohno Y, Picard A, Salanova M, Schiffl G, Blottner D, Musarò A, Ohira Y, Betto R, Conte D, Schiaffino S.

PLoS One. 2012;7(3):e33232. doi: 10.1371/journal.pone.0033232. Epub 2012 Mar 28.

Supplemental Content

Loading ...
Support Center